Literature DB >> 15955951

A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia.

R Benecke1, W H Jost, P Kanovsky, E Ruzicka, G Comes, S Grafe.   

Abstract

A new botulinum toxin type A free of complexing proteins (NT 201) was compared with BOTOX in patients with cervical dystonia by means of a double-blind noninferiority trial. Four hundred sixty-three patients received IM injections of 70 to 300 U of NT 201 or BOTOX and were followed up over 16 weeks. The study clearly shows that NT 201 is at least as effective and safe as BOTOX.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15955951     DOI： 10.1212/01.WNL.0000163767.99354.C3

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  82 in total

1.  Measuring the potency labelling of onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)) in an LD50 assay.

Authors:  Dirk Dressler; Gerd Mander; Klaus Fink
Journal:  J Neural Transm (Vienna)       Date:  2011-10-05       Impact factor: 3.575

2.  [Pharmacology of botulinum toxin drugs].

Authors:  D Dressler
Journal:  HNO       Date:  2012-06       Impact factor: 1.284

Review 3.  Botulinum neurotoxin - from laboratory to bedside.

Authors:  K A Foster; H Bigalke; K R Aoki
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

Review 4.  Botulinum toxin therapy for cervical dystonia.

Authors:  J Jankovic
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

Review 5.  [Pharmacological aspects of therapeutic botulinum toxin preparations].

Authors:  D Dressler
Journal:  Nervenarzt       Date:  2006-08       Impact factor: 1.214

Review 6.  The treatment of cervical dystonia with botulinum toxins.

Authors:  C L Comella
Journal:  J Neural Transm (Vienna)       Date:  2007-11-12       Impact factor: 3.575

Review 7.  From poison to remedy: the chequered history of botulinum toxin.

Authors:  F J Erbguth
Journal:  J Neural Transm (Vienna)       Date:  2007-04-26       Impact factor: 3.575

Review 8.  Treatment of dystonia.

Authors:  Mary Ann Thenganatt; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

9.  A Phase III Study of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines.

Authors:  Matthias Imhof; Ulrich Kühne
Journal:  J Clin Aesthet Dermatol       Date:  2011-10

10.  [Does dilution have an impact on cosmetic results with BoNT/A? Complex-protein-free BoNT/A for treatment of glabella lines].

Authors:  W Prager; I Zschocke; C Reich; L Brocatti; K Henning; V Steinkraus
Journal:  Hautarzt       Date:  2009-10       Impact factor: 0.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.